Photo by freestocks from unsplash
In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al.… Click to show full abstract
In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in combination with immune checkpoint blockade.
Keywords:
kras heart;
immune evasion;
mutant kras;
tumor immune;
heart tumor
Journal Title: Immunity
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Immunity
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!